Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX

被引：274

作者：

Michelakos, Theodoros ^{[1
]}

Pergolini, Ilaria ^{[1
]}

Fernandez-del Castillo, Carlos ^{[1
]}

Honselmann, Kim C. ^{[1
]}

Cai, Lei ^{[1
]}

Deshpande, Vikram ^{[2
]}

Wo, Jennifer Y. ^{[3
]}

Ryan, David P. ^{[4
]}

Allen, Jill N. ^{[4
]}

Blaszkowsky, Lawrence S. ^{[4
]}

Clark, Jeffrey W. ^{[4
]}

Murphy, Janet E. ^{[4
]}

Nipp, Ryan D. ^{[4
]}

Parikh, Aparna ^{[4
]}

Qadan, Motaz ^{[1
]}

Warshaw, Andrew L. ^{[1
]}

Hong, Theodore S. ^{[3
]}

Lillemoe, Keith D. ^{[1
]}

Ferrone, Cristina R. ^{[1
]}

机构：

[1] Harvard Med Sch, Dept Surg, Massachusetts Gen Hosp, 15 Parkman St, Boston, MA 02114 USA

[2] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA

[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA

[4] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA

来源：

ANNALS OF SURGERY | 2019年 / 269卷 / 04期

关键词：

FOLFIRINOX; neoadjuvant therapy; pancreatic cancer; PHASE-II; THERAPY; RADIOTHERAPY; GEMCITABINE; RESECTION; CHEMORADIATION; ADENOCARCINOMA; CHEMOTHERAPY;

D O I：

10.1097/SLA.0000000000002600

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Objective: The aim of this study was to determine (1) whether preoperative factors can predict resectability of borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant FOLFIRINOX, (2) which patients might benefit from adjuvant therapy, and (3) survival differences between resected BR/LA patients who received neoadjuvant FOLFIRINOX and upfront resected patients. Background: Patients with BR/LA PDAC are often treated with FOLFIRINOX to obtain a margin-negative resection, yet selection of patients for resection remains challenging. Methods: Clinicopathologic data of PDAC patients surgically explored between 04/2011-11/2016 in a single institution were retrospectively collected. Results: Following neoadjuvant FOLFIRINOX, 141 patients were surgically explored (BR: 49%, LA: 51%) and 110 (78%) were resected. Resected patients had lower preoperative CA 19-9 levels (21 vs 40U/mL, P = 0.03) and smaller tumors on preoperative computed tomography (CT) scan (2.3 vs 3.0 cm, P = 0.03), but no predictors of resectability were identified. Median overall survival (OS) was 34.2 months from diagnosis for all FOLFIRINOX patients and 37.7 months for resected patients. Among resected patients, preoperative CA 19-9 >100 U/mL and >8 months between diagnosis and surgery predicted a shorter postoperative disease-free survival (DFS); Charlson comorbidity index >1, preoperative CA 19-9 >100 U/mL and tumor size (>3.0 cm on CT or >2.5 cm on pathology) predicted decreased OS. DFS and OS were significantly better for BR/LA PDAC patients treated with neoadjuvant FOLFIRINOX compared with upfront resected patients (DFS: 29.1 vs 13.7, P < 0.001; OS: 37.7 vs 25.1 months from diagnosis, P = 0.01). Conclusion: BR/LA PDAC patients with no progression on neoadjuvant FOLFIRINOX should be offered surgical exploration. Except size, traditional pathological parameters fail to predict survival among resected FOLFIRINOX patients. Resected FOLFIRINOX patients have survival that appears to be superior than that of resectable patients who go directly to surgery.

引用

页码：733 / 740

页数：8

共 22 条

[1] Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer [J].

Aldakkak, Mohammed ;

Christians, Kathleen K. ;

Krepline, Ashley N. ;

George, Ben ;

Ritch, Paul S. ;

Erickson, Beth A. ;

Johnston, Fabian M. ;

Evans, Douglas B. ;

Tsai, Susan .

HPB, 2015, 17 (10) :942-952

[2] Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes? [J].

Bednar, Filip ;

Zenati, Mazen S. ;

Steve, Jennifer ;

Winters, Sharon ;

Ocuin, Lee M. ;

Bahary, Nathan ;

Hogg, Melissa E. ;

Zeh, Herbert J., III ;

Zureikat, Amer H. .

ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (05) :1406-1413

[3] Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer [J].

Ben-Josef, E ;

Shields, AF ;

Vaishampayan, U ;

Vaitkevicius, V ;

El-Rayes, BF ;

McDermott, P ;

Burmeister, J ;

Bossenberger, T ;

Philip, PA .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (02) :454-459

[4] Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma [J].

Boone, Brian A. ;

Steve, Jennifer ;

Zenati, Mazen S. ;

Hogg, Melissa E. ;

Singhi, Aatur D. ;

Bartlett, David L. ;

Zureikat, Amer H. ;

Bahary, Nathan ;

Zeh, Herbert J., III .

ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (13) :4351-4358

[5] Updated Long-Term Outcomes and Prognostic Factors for Patients With Unresectable Locally Advanced Pancreatic Cancer Treated With Intraoperative Radiotherapy at the Massachusetts General Hospital, 1978 to 2010 [J].

Cai, Sophie ;

Hong, Theodore S. ;

Goldberg, Saveli I. ;

Fernandez-del Castillo, Carlos ;

Thayer, Sarah P. ;

Ferrone, Cristina R. ;

Ryan, David P. ;

Blaszkowsky, Lawrence S. ;

Kwak, Eunice L. ;

Willett, Christopher G. ;

Lillemoe, Keith D. ;

Warshaw, Andrew L. ;

Wo, Jennifer Y. .

CANCER, 2013, 119 (23) :4196-4204

[6] Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement [J].

Callery, Mark P. ;

Chang, Kenneth J. ;

Fishman, Elliot K. ;

Talamonti, Mark S. ;

Traverso, L. William ;

Linehan, David C. .

ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (07) :1727-1733

[7] Meta-analysis of radical resection rates and margin assessment in pancreatic cancer [J].

Chandrasegaram, M. D. ;

Goldstein, D. ;

Simes, J. ;

Gebski, V. ;

Kench, J. G. ;

Gill, A. J. ;

Samra, J. S. ;

Merrett, N. D. ;

Richardson, A. J. ;

Barbour, A. P. .

BRITISH JOURNAL OF SURGERY, 2015, 102 (12) :1459-1472

[8] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].

Conroy, Thierry ;

Desseigne, Francoise ;

Ychou, Marc ;

Bouche, Olivier ;

Guimbaud, Rosine ;

Becouarn, Yves ;

Adenis, Antoine ;

Raoul, Jean-Luc ;

Gourgou-Bourgade, Sophie ;

de la Fouchardiere, Christelle ;

Bennouna, Jaafar ;

Bachet, Jean-Baptiste ;

Khemissa-Akouz, Faiza ;

Pere-Verge, Denis ;

Delbaldo, Catherine ;

Assenat, Eric ;

Chauffert, Bruno ;

Michel, Pierre ;

Montoto-Grillot, Christine ;

Ducreux, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825

[9] FOLFIRINOX in Locally Advanced Pancreatic Cancer: The Massachusetts General Hospital Cancer Center Experience [J].

Faris, Jason E. ;

Blaszkowsky, Lawrence S. ;

McDermott, Shaunagh ;

Guimaraes, Alexander R. ;

Szymonifka, Jackie ;

Huynh, Mai Anh ;

Ferrone, Cristina R. ;

Wargo, Jennifer A. ;

Allen, Jill N. ;

Dias, Lauren E. ;

Kwak, Eunice L. ;

Lillemoe, Keith D. ;

Thayer, Sarah P. ;

Murphy, Janet E. ;

Zhu, Andrew X. ;

Sahani, Dushyant V. ;

Wo, Jennifer Y. ;

Clark, Jeffrey W. ;

Fernandez-del Castillo, Carlos ;

Ryan, David P. ;

Hong, Theodore S. .

ONCOLOGIST, 2013, 18 (05) :543-548

[10] Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer [J].

Ferrone, Cristina R. ;

Marchegiani, Giovanni ;

Hong, Theodore S. ;

Ryan, David P. ;

Deshpande, Vikram ;

McDonnell, Erin I. ;

Sabbatino, Francesco ;

Santos, Daniela Dias ;

Allen, Jill N. ;

Blaszkowsky, Lawrence S. ;

Clark, Jeffrey W. ;

Faris, Jason E. ;

Goyal, Lipika ;

Kwak, Eunice L. ;

Murphy, Janet E. ;

Ting, David T. ;

Wo, Jennifer Y. ;

Zhu, Andrew X. ;

Warshaw, Andrew L. ;

Lillemoe, Keith D. ;

Fernandez-del Castillo, Carlos .

ANNALS OF SURGERY, 2015, 261 (01) :12-17

← 1 2 3 →